Blue Jet Healthcare Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/4rwgaa28f9vizhtlk435fgs5.pdf

Key Takeaways


Contrast Media: The Quarter's Standout and FY27's Growth Driver

Karuppannan: "In this particular CDMO activity, one should not look at a monthly or a quarterly. I think as long as we get that annual number right, I think that would be a better way to forecast."

PI/API: Destocking Over, Normalization Begins

Singh: "I think over the last 6 quarters, the work that has been happening, very intensive work has been happening, and we are getting to a stage when that will all start fructifying."

The Capex Super-Cycle: Vizag, Mahad, Hyderabad

Singh: "while FY26 might have been flattish, the year was foundational because we are sowing the seeds for doubling our capacity and doubling our chemistry platforms in R&D."

New Verticals: Peptides, Sweeteners, and the Japanese Trial

Singh: "On the peptide side also, our starting point is doing the building blocks for the peptides or doing the peptide fragments... As we advance and we get clientele and we get experience in doing the peptide blocks, doing the final peptide will be the natural corollary."

Margins: Compressed in FY26, Q1 Will Set the Baseline for FY27

Singh: "If you look at our leading financial metrics and indicators, I think they are one of the best in the industry. So I don't see why you should be asking that we are not optimizing for the near term."

Customer & Competitive Dynamics


Guidance & Commitments

CommitmentSpecificsTimeline
Contrast media growthDouble-digit growth in FY27, backed by certain customer visibilityFY27
Contrast media new launches3 to 4 new product launches; 1-2 validations and 1 commercial launchFY27
PI/API recoveryNormalize growth and grow over FY25 peak sale for the cardiovascular drug intermediateFY27
PI/API pipeline conversion2 of ~20 active RFPs expected to move into commercializationFY27
Mahad backward integrationPlant commences production; slow ramp-upH2 FY27
Hyderabad R&D centerGoes live, focused on peptides, GLP-1, biocatalystsH2 FY27
Vizag greenfield Phase 1Manufacturing blocks for contrast media, sweeteners, pharma intermediates24-30 months from now
FY27 capex₹400 cr across Vizag, Mahad completion, and AmbernathFY27
Margin visibilityQ1 will give a good representation of cost structures and marginsQ1 FY27
Artificial sweetenerDeliver key validation; trial quantities to shipComing quarters

Key Metrics

MetricQ4 FY26
Revenue₹235 cr, +22% QoQ and -31% YoY
Contrast media revenue₹193 cr, +55% QoQ and +91% YoY
PI/API revenue₹2.4 cr, vs ₹40 cr in Q3 and ₹196 cr in Q4 FY25
Artificial sweetener revenue₹37 cr, +43% QoQ and -24% YoY
Gross margin56%, vs 52% in Q3 and 55% in Q4 FY25
FY26 full-year revenue₹947 cr, -8% vs FY25
FY26 full-year contrast media revenue₹495 cr, +23% vs FY25
FY26 full-year PI/API revenue₹298 cr, -35% vs FY25
FY26 full-year artificial sweetener revenue₹131 cr, -2% vs FY25
FY26 full-year gross margin54%, vs 55% in FY25
FY26 EBITDA margin31%, vs 37% in FY25
FY26 PAT margin26%, vs 30% in FY25
FY26 other income₹69 cr, vs ₹46 cr in FY25, includes exchange gain of ₹36 cr and insurance claim income of ₹5 cr
FY26 cash flow from operating activities₹334 cr
Liquid financial assets at FY26 end₹400 cr, vs ₹306 cr in FY25, debt-free
Total CWIP as of March 2026₹301 cr, predominantly Mahad and Vizag land acquisition
Proposed capex for FY27approximately ₹400 cr, for Vizag greenfield, Mahad completion, and Ambernath additions
Vizag total capex planapproximately ₹1,000 cr over approximately 3 years
Hyderabad R&D center planned investmentapproximately ₹40 cr
Contrast media FY27 annual forecast from customermid-single digit growth
Energy consumption from renewables70%
Contrast media new product launches expected in FY273 to 4
Active RFPs in PI and CDMO segmentapproximately 20, primarily chronic therapeutic areas including GLP-1 and peptide building blocks
PI/CDMO opportunities expected to commercialize in FY272
High conviction commercial stage lateral entry opportunities2, dedicated capacity factored into Vizag planning